


## Diphenhydramine-d<sub>6</sub> hydrochloride

<b>Cat. No.:</b>	HY-B0303AS
<b>CAS No.:</b>	1189986-72-8
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>16</sub> D <sub>6</sub> ClNO
<b>Molecular Weight:</b>	297.85
<b>Target:</b>	Histamine Receptor; Endogenous Metabolite; Isotope-Labeled Compounds
<b>Pathway:</b>	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Metabolic Enzyme/Protease; Others
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (335.74 mM; Need ultrasonic)  
H<sub>2</sub>O : 100 mg/mL (335.74 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
	Concentration				
	1 mM		3.3574 mL	16.7870 mL	33.5739 mL
	5 mM		0.6715 mL	3.3574 mL	6.7148 mL
	10 mM		0.3357 mL	1.6787 mL	3.3574 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Diphenhydramine-d<sub>6</sub> (hydrochloride) is the deuterium labeled Diphenhydramine hydrochloride. Diphenhydramine hydrochloride is a first-generation histamine H<sub>1</sub>-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can cross the ovine blood-brain barrier (BBB)[1][2].

#### IC<sub>50</sub> & Target

H<sub>1</sub> Receptor

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

[2]. Simons FE. H1-receptor antagonists. Comparative tolerability and safety. *Drug Saf.* 1994;10(5):350-380.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA